Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through our clinical improvement programs and research.
We are committed to the goal of extending life expectancy from 47 to 55 years by 2026.
These include the Australian Cystic Fibrosis Data Registry (ACFDR), Peer Reviews, Standards of Care, Infection Control Guidelines, Transition Guidelines and Centre Directors Forums.
CFA is the peak patient body in Australia and supports the broad cystic fibrosis community through advocacy, research, and clinical improvement. A new era of medications is upon us, medications capable of targeting the basic defect in the cells of people with CF. These medications will have an unprecedented positive impact on the lives of people with CF.
> Increased access to a wide-range of high-quality treatments to reduce the burden of the disease.
> Delivery of world-class clinical care with Australian standards setting international benchmarks.
> Enhancing the capability and capacity of research and innovation in Australia into CF.
It is time to plan for the future.
View our 2021 – 2026 Strategic Plan.
CFA funds the management and ongoing development of the ACFDR.
The ACFDR is a vital tool for the CF community as it stimulates ground-breaking research, supports clinical teams to improve care, monitors the safety of new medicines and through the ACFDR Annual Report, gives people with CF and their families up-to-date information about the condition.
Learn More about our Data Registry HERE
Contact your Consumer Representative
Did you know?
For each of our projects and programs, we have dedicated consumer representatives who provide input into the work Cystic Fibrosis Australia partake in.
If you would like to submit any feedback or comments to our Consumer Representatives, please complete this form and your reps will take this on board.